Introduction
============

Glucocorticoids are very effective therapy for asthma and numerous studies have shown that they reduce asthma symptoms, exacerbations and bronchial hyperresponsiveness. The benefit/risk ratio of glucocorticoid therapy was enhanced further in the 1960's when topical delivery devices were introduced. Inhaled glucocorticoids are now the first line therapy in patients with all but the mildest disease.

The vast majority of asthmatics are controlled satisfactorily with regular inhaled glucocorticoids with or without the addition of short- or long-acting bronchodilators. In such patients, particularly those on low to moderate dosages of inhaled glucocorticoids, it is hard to conceive of a safer or more effective therapy.

Unfortunately, however, a proportion of patients develop severe disease which is relatively or totally refractory to glucocorticoid therapy. The possible etiology of this condition will be discussed in subsequent paragraphs, but the existence of the phenomenon implies that asthma is heterogeneous in terms of its susceptibility to inhibition by glucocorticoids, and possibly therefore also in terms of its etiology.

While the percentages of patients with glucocorticoid resistant asthma are small, these patients consume a significant proportion of medical resources in terms of both time and money ([@b10]). Regardless of costs, there is an urgent need to provide alternative therapies for these patients, who often have severely impaired quality of life not only from the severity of their symptoms but from the effects of excessive glucocorticoid exposure.

Difficult asthma
================

Definition
----------

Although any clinician managing asthmatic patients will have a clear picture of "difficult to treat" disease, it is in fact extraordinarily difficult to define this condition accurately, particularly for the purposes of research.

Definition of "difficult asthma" could include the following:

-   Confirmation of the diagnosis of asthma

-   An unusually poor response to therapy

-   Chronicity of the problem.

Problems arise with all of these concepts. Obviously it is essential to be as certain as possible of a primary diagnosis of asthma. This diagnosis of course rests on a clinical history of typical symptoms and physiological evidence of variable and reversible airways obstruction. Often, however, on presentation to a specialist, it may not be possible to obtain contemporary evidence of these features if the patient is already established on therapy. Clearly it is essential to search for and eliminate other possible alternative or associated diagnoses ([Table 1](#tbl1){ref-type="table"}). Allergic bronchopulmonary aspergillosis and pulmonary eosinophilic syndromes (for example, pulmonary eosinophilia or Churg-Strauss syndrome) may be considered unique diseases which encompass some of the clinical features of asthma and which are often difficult to treat: these are probably best considered outside the definition of "difficult" asthma. Vocal cord dysfunction characterized by paradoxical adduction of the vocal cords may masquerade as and co-exist with asthma ([@b79]). Other respiratory conditions such as chronic bronchitis or bronchiectasis may also co-exist with asthma, but there are very few studies assessing the effect of these in the long term on asthma severity or control.

###### 

Diagnoses that may masquerade as difficult/therapy-resistant asthma

  ------------------------------------------------------------------------------
  **In children**
  Obliterative bronchiolitis
  Vocal cord dysfunction
  Bronchomalacia
  Inhaled foreign bodies
  Cystic fibrosis
  Recent aspiration (particularly in handicapped children)
  Developmental abnormalities of the upper airway
  Immunoglobulin deficiencies
  Primary ciliary dyskinesia
  **In adults**
  Cystic fibrosis
  Bronchiectasis
  Inhaled foreign body
  Tracheobronchomalacia
  Recurrent aspiration
  Chronic obstructive pulmonary disease
  Congestive cardiac failure
  Tumours in or impinging on central airways
  Obstructive bronchiolitis
  Vocal cord dysfunction
  Bronchial amyloidosis
  **As part of the asthmatic diathesis**
  Allergic bronchopulmonary aspergillosis
  Pulmonary eosinophilic syndromes (eg, Churg-Strauss, pulmonary eosinophilia)
  ------------------------------------------------------------------------------

"Resistance to therapy" is usually identified as failure of asthma "control" despite therapy. This does, however, imply that all patients who are resistant to glucocorticoid therapy will necessarily have severe disease, which may not be the case. It also begs the question of what is used to define asthma "control". This is usually assessed in terms of symptoms and requirement for short-acting β2-agonist medication. Patients vary in their perception of airflow limitation and poor perceivers may be particularly prone to severe attacks ([@b57]). Other techniques commonly used to define asthma "control" include objective monitoring of airways obstruction and the numbers of exacerbations experienced by patients defined according to various criteria (such as, for example, those requiring systemic glucocorticoid therapy). The international guidelines (Global Initiative for Asthma 1995) define asthma severity in terms of airways obstruction as measured by PEF or FEV~1~. Nevertheless, the presence of persistent airways obstruction does not necessarily reflect loss of asthma "control". The value of using asthma biomarkers to assess the amount of airways inflammation and the relationship of these measurements to asthma control is also currently under close scrutiny. There is little evidence to date, however, that short-term measurements of biomarkers can predict the severity and chronicity of symptoms. Consequently, the concept of "difficult asthma" at present requires our third dimension of chronicity of observation. Increasingly, the amount of inhaled glucocorticoid and other therapy needed for the control of asthma, rather than quantification of symptoms or of lung function is being used to define asthma severity ([@b17]).

A number of factors may contribute to poor asthma "control", and must be taken into account before labeling the patient as glucocorticoid refractory or resistant ([Table 2](#tbl2){ref-type="table"}). Since response to therapy is part of the definition of "difficult" asthma, the question of patient adherence to therapy must be considered. Compliance with inhaled glucocorticoid therapy in asthma has been reported to be very poor ([@b54]; [@b89]) and it might be expected, although there is actually little hard evidence ([@b16]; [@b73]) that this contributes to poor asthma control. Insufficient therapy is probably a much bigger contributor to poor asthma control worldwide ([@b85]). Psychosocial factors, which may be linked with or compounded by poor patient compliance and lack of appropriate medical care ([@b74]; [@b106]; Chung et al 1999; [@b6]) have also been implicated in poor asthma control and asthma deaths. Incorrect diagnosis of respiratory symptoms as asthma is a cause of apparent poor responsiveness to asthma therapy, and this is not as uncommon as might be expected, even in specialist asthma centres (Robinson et al 2000). Although a precise mechanistic link between gastro-esophageal reflux and a decline in asthma control is not established, varying degrees of improvement in asthma have been observed when concomitant gastro-esophageal reflux has been treated ([@b99]). Targeted treatment of rhinosinusitis, often present concurrently with asthma, can lead to specific improvement in asthma control (Corren et al 1982). Although attention to these comorbid factors seems pertinent, there is little evidence that they exert a global impact on the response of asthmatics to therapy: indeed one study ([@b39]), although showing a prevalence of comorbid conditions in patients with poorly controlled asthma, failed to show that such conditions were more prevalent in asthmatics who responded poorly to glucocorticoids. Moreover, targeted treatment of identified comorbidities barely altered asthma-related quality of life in those patients with glucocorticoid-insensitive disease.

###### 

Factors that may be responsible for poor asthma control Incorrect diagnosis

  --------------------------------------
  Poor compliance/adherence to therapy
  Psychosocial and emotional factors
  Inadequate medical facilities
  Poor access to medical facilities
  Inadequate treatment
  Exposure to allergens
  Viral respiratory tract infections
  Indoor/outdoor pollution
  Gastro-oesophageal reflux
  Rhinosinusitis
  Genetic factors
  --------------------------------------

Clinical and pathophysiological phenotypes of "difficult" asthma
----------------------------------------------------------------

Studies attempting to delineate clinical phenotypes of "difficult" asthma are ongoing in the United States and Europe ([@b28]; [@b27]; [@b75]). The ENFUMOSA study ([@b28]) showed that severe asthmatics were more likely to be female, more likely to be aspirin sensitive and less likely to be atopic. Although some clinical subgroups such as "brittle" asthmatics and glucocorticoid resistant asthmatics are recognized as being difficult to treat, these studies have not yet provided a viable framework upon which to predict responsiveness to therapy on clinical grounds.

Attempts have also been made to delineate pathophysiological features of asthma which predict a poor response to therapy. The problem with such studies in severe asthmatics is that it is difficult to discriminate a priori abnormalities from the effects of the high dosages of glucocorticoid and other therapies that these patients are inevitably receiving. Much circumstantial evidence implicates eosinophils in asthma pathogenesis, although as with all inflammatory leukocytes the precise mechanisms by which these cells cause the clinical features of asthma, and why these mechanisms might be therapy resistant, remain unclear. One study described a group of apparently therapy resistant severe asthmatics with high numbers of airways eosinophils ([@b94]), but there is evidence ([@b102]) that such patients may respond if treated with sufficiently high dosages of glucocorticoid. On the other hand, Wenzel and colleagues ([@b108], [@b109]) have shown that it is possible to delineate groups of severe, glucocorticoid dependent asthmatics with numbers of airways eosinophils within the range observed in normal controls. One of these studies suggested that these patients also had increased airways neutrophils, while the other did not. The airways changes associated with asthma which are collectively termed "remodeling" (lay down of new proteins, mucous hyperplasia, neovascularisation, smooth muscle hypertrophy/hyperplasia) could conceivably be resistant to therapy and cause irreversible airways blockage, although this has never been formally demonstrated. Clinically, patients with severe asthma and irreversible airways obstruction show tomographic abnormalities suggestive of remodeling ([@b11]). Whether remodeling is caused by inflammatory cells or cytokines, or both, is still not clear. In animals, over expression of the cytokine IL-13 alone in the airways reproduced all the features of airways remodeling ([@b56]); glucocorticoid administration abolished the associated cellular infiltrate but not the remodeling changes. In human studies, anti-IL-5 therapy was shown to reduce lay down of extracellular matrix proteins in the lungs while partly but not completely abolishing the infiltration of eosinophils ([@b29]), leaving the question open whether or not leukocytes such as eosinophils play an indispensable role in this process. It has been suggested that one etiological factor in intrinsic asthma is autoimmune attack of the airways, for example by autoantibodies (Lasalle et al 1993; [@b77]).

In summary, despite this wealth of possible aetiological factors which may contribute to loss of asthma control, it is still not clear which of these can be clearly implicated in the genesis of glucocorticoid refractory or resistant asthma. It is furthermore not clear whether these aetiological factors lead to specific features of asthma pathology or contribute specifically to any feature of the natural history of the disease.

Environmental factors and "difficult" asthma
--------------------------------------------

### Oxidative stress and anti-oxidants

Markers of oxidative stress such as 8-isoprostane are elevated in severe asthma ([@b53]; [@b55]). Cigarette smoking and poor dietary anti-oxidant intake are potential sources of oxidative stress, and it has been shown that asthmatics who smoke are clinically more resistant to glucocorticoid therapy ([@b14]). Oxidative stress can affect several aspects of glucocorticoid activity, for example through activation of the transcriptional regulatory protein AP-1 or by reducing nuclear translocation of the glucocorticoid receptor (see below).

### Viral and other infections

Recurrent respiratory tract infections, most of these viral, increase the risk of asthma exacerbation ([@b103]), although it is not clear whether they alter responsiveness to glucocorticoid therapy. Very little is known about the mechanisms by which viral infections exacerbate asthma, and this field deserves much more study. There is also some evidence for the involvement of latent chlamydial ([@b32]) and, at least in animal models, adenoviral infections ([@b112]).

### Allergen exposure

There is abundant evidence (summarized by [@b68]; [@b12]) that exposure of sensitized asthmatics to clinically relevant allergens requires increased glucocorticoid therapy for disease control. It has been shown ([@b80]) that seasonal allergen exposure of atopic asthmatics increases refractoriness of their T cells to glucocorticoid in an allergen-specific and IL-2 and IL-4 dependent fashion (see also below).

### Microbial superantigens

There is evidence in other atopic diseases, particularly atopic dermatitis that colonization of the target organ (which is common) or infection with *Staphylococcus aureus* confers resistance to glucocorticoid therapy. Preferential expansion of T cells expressing particular antigen receptor Vβ chains has been observed in poorly controlled asthmatics ([@b36]), suggesting activation by microbial superantigen. In addition to T cell activation, superantigen has been shown to confer T cell resistance to glucocorticoid by induction of the β-isoform of the glucocorticoid receptor and by phosphorylation of the glucocorticoid receptor ([@b37]; [@b69]).

The concept of glucocorticoid resistant asthma
==============================================

The diagnosis of glucocorticoid resistant asthma is essentially one of exclusion. Before it can be diagnosed, it must be ensured that the diagnosis of asthma is correct and that factors contributing to poor asthma control have been eliminated as far as is possible. These stages have been formalized ([@b110]) as follows:

-   Establish/confirm the diagnosis of asthma (consider differential diagnosis -- see [Table 1](#tbl1){ref-type="table"});

-   Ensure that adequate dosages of glucocorticoids are reaching the airways (compliance, inhaler technique, metabolic factors which may increase glucocorticoid clearance);

-   Exclude ongoing exposure to provoking agents (smoke, irritants, allergens, etc.);

-   Rule out and eliminate as far as possible other potential aggravating conditions (chronic sinusitis, esophageal reflux, drugs which may exacerbate asthma, etc.);

-   Rationalize inhaled β2-agonist therapy;

-   Introduce a strict management plan to assess response to therapy which will typically last for weeks or sometimes months.

Even when all factors which may abrogate the effects of glucocorticoid therapy are eliminated or minimized as far as possible, there remains a group of patients who show little or no response of airways obstruction to glucocorticoid therapy. This concept was first proposed over 30 years ago ([@b91]). In this study, the authors described asthmatic patients in whom disease was poorly controlled, and the typical peripheral blood eosinopaenic response diminished, on large oral dosages of glucocorticoids. Later, it was recognised that there were some asthmatics in whom the diurnal pattern of airways obstruction is little altered by glucocorticoid therapy ([@b15]).

The first attempt to define glucocorticoid resistant asthma in objective terms ([@b13]) was based on changes in base line FEV~1~ following a 14 day course of oral prednisolone (40 mg/day). Patients showing improvements of \<15% of baseline were classified as resistant, whereas those showing improvements of 30% or more were considered glucocorticoid sensitive. All patients, in contrast, showed marked improvement in FEV~1~ in response to inhaled β2-agonists, indicating that, at least in this group of patients, the glucocorticoid response did not reflect "irreversible" airways obstruction (although, as discussed, this may be a factor in other patients). Clearly, these FEV~1~ responses represent opposite ends of a continuum of clinical response. Most subsequent studies have employed definitions of glucocorticoid sensitive and resistant asthma similar or identical to the above, in both adults and children ([@b50]; [@b5]). The possibility that glucocorticoid "resistant" subjects who show no clinical response following two weeks of oral glucocorticoid therapy might nevertheless respond following more protracted therapy has never been formally addressed, although it was shown ([@b51]) that 90% of severe asthmatic children showing an improvement in FEV~1~ \>15% of baseline on high-dosage oral glucocorticoid therapy did so within 10 days.

On the basis of these studies, a workshop of experts on glucocorticoid resistant asthma proposed that this should be defined by the failure to improve baseline morning pre-bronchodilator FEV~1~ by more than 15% of the baseline value following at least 14 days of therapy with prednisolone 40 mg daily or its equivalent ([@b65]). One weakness of this definition is that patients with refractory asthma are typically taking large dosages of inhaled glucocorticoid, the therapeutic effect of which may have reached a "ceiling" limiting further clinical response. Nevertheless, patients with complete glucocorticoid resistance show not only a failure of response in terms of FEV~1~, but also, in general, an ability to tolerate reduction of glucocorticoid dosages without significant change in disease activity. In addition, they typically show little increase in FEV~1~ even with more protracted, much higher dosages of systemic glucocorticoids. This is in distinction to glucocorticoid "dependent" asthmatics, who may not show a response in FEV~1~ of 15% or more during a 14 day trial of systemic glucocorticoid therapy, but rapidly deteriorate when this therapy is withdrawn. Although it is assumed that these patients fall at the end and near end of a spectrum of glucocorticoid responsiveness in asthma, it is not certain whether these two groups of patients have fundamentally different abnormalities leading to glucocorticoid refractoriness. Although glucocorticoid resistant patients may show a degree of fixed airways obstruction, many show marked diurnal variability in PEF and a brisk bronchodilator response ([@b5]; [@b50]).

It is inherent in the diagnosis of glucocorticoid resistant asthma that the diagnosis of asthma has been made correctly and that factors confounding therapy have been eliminated or reduced as far as possible. Most clinical descriptions of glucocorticoid resistant asthma emphasize the following common clinical features ([@b98]):

-   Persistent symptoms despite optimal therapy;

-   Chronic airflow limitation with FEV~1~\<60% predicted in adults and \<80% predicted in children;

-   Failure to achieve an increase in morning pre-bronchodilator FEV~1~ of \>60% predicted despite systemic glucocorticoid therapy (at least 40 mg/day of prednisolone or its equivalent given for at least 14 days);

-   Frequent nocturnal symptoms with significant "morning dipping" of PEF;

-   Poor clinical and spirometric response to oral glucocorticoid therapy, with \<15% improvement in pre-bronchodilator FEV~1~ following a trial of oral glucocorticoid therapy as specified.

It should be noted finally that, although glucocorticoid resistant patients are identified by definition on the basis of having severe disease which does not respond to therapy, it cannot be excluded that patients with milder disease may also nevertheless be glucocorticoid resistant. It would require a large and protracted study to investigate this hypothesis, but the point has a bearing on whether or not the severity of disease itself actually regulates, at least in part, glucocorticoid responsiveness (see below).

Mechanisms of glucocorticoid resistant asthma
=============================================

Despite several decades of usage of glucocorticoids as anti-inflammatory agents, in general very little is known about the precise mechanisms by which they ameliorate inflammatory diseases. A good review is provided by [@b46]. Glucocorticoids exert a number of generalized anti-inflammatory activities, such as capillary vasoconstriction and reduction of vascular permeability, which may be relevant to suppression of inflammation however caused. In the case of asthma, it is now generally accepted that bronchial mucosal inflammation is a fundamental feature of disease pathogenesis. Despite the doubts about the precise roles (if any) of effector inflammatory leukocytes discussed above, a working scenario is that eosinophils are regarded as pro-inflammatory effector cells the products of which damage the bronchial mucosa, causing variable airways obstruction and bronchial hyperresponsiveness. Selective eosinophil accumulation and activation in asthma is in turn brought about by the release of eosinophil-active cytokines, particularly IL-3, IL-5 and GM-CSF, principally from activated T cells but also partly from other inflammatory cells, including mast cells and eosinophils themselves ([@b22]).

If a mechanistic role for leukocytes such as eosinophils in asthma has become less clear recently, there remains much better evidence that glucocorticoid therapy which results in amelioration of asthma is associated with reduced activation of, and synthesis of asthma-relevant cytokines by activated T cells. For example, elevated percentages of peripheral blood CD4, but not CD8 T cells from patients with exacerbation of asthma expressed mRNA encoding IL-3, IL-5 and GM-CSF but not IL-2 and IFN-γ as compared with controls ([@b23]). Spontaneous secretion of the corresponding cytokines was also demonstrable in these patients using an eosinophil survival-prolonging assay. The percentages of CD4 T cells expressing mRNA encoding asthma-relevant cytokines, as well as spontaneous secretion of these cytokines was reduced in association with glucocorticoid therapy and clinical improvement. In a double-blind, parallel group study ([@b88]), therapy of mild atopic asthmatics with oral prednisolone, but not placebo, resulted in clinical improvement associated with a reduction in the percentages of BAL fluid cells expressing IL-5 and IL-4 and an increase in those expressing γ. These and other studies have provided overwhelming evidence in support of the general hypothesis that, in asthma, activated CD4 T cells secrete cytokines that are relevant to asthma pathogenesis, through direct actions on the airways mucosa or activation of inflammatory leukocytes such as eosinophils, and that glucocorticoids exert their anti-asthma effect at least partly by reducing the synthesis of cytokines by these cells.

Functional T cell abnormalities in glucocorticoid resistant asthma
------------------------------------------------------------------

A reasonable hypothesis is, then, that glucocorticoid resistant asthma may reflect refractoriness of T cells to glucocorticoid inhibition. A pioneering study in this field ([@b84]) showed that when peripheral blood mononuclear cells from glucocorticoid sensitive and resistant asthmatics were cultured with the T cell mitogen phytohaemagglutinin (PHA) in soft agar in vitro, methylprednisolone (10^−8^ M) produced a lesser degree of inhibition of colony formation by the cells from the resistant asthmatics, suggesting impaired T cell inhibition by glucocorticoids in these patients. This observation was followed up with two reports from the author's laboratory ([@b20], [@b21]) characterizing peripheral blood T cells of glucocorticoid sensitive and resistant asthmatics. In summary, it was demonstrated in these reports that PHA-induced proliferation of peripheral blood T cells was inhibited by dexamethasone at therapeutic concentrations in glucocorticoid sensitive, but not resistant asthmatics. This resistance was not absolute but relative, reflecting a shift in the concentration-response curve for inhibition. In other words, T cells from glucocorticoid resistant asthmatics can be inhibited by glucocorticoids, but only at concentrations requiring glucocorticoid dosages that most physicians would not contemplate using for protracted periods in clinical practice. Consistent with this, it was demonstrated ([@b21]) that elevated percentages of peripheral blood T cells expressed the activation markers in CD25 and HLA-DR in glucocorticoid resistant, as compared with sensitive asthmatics, with no differences in total cell numbers, suggesting persistent T cell activation in the resistant patients despite glucocorticoid therapy.

In glucocorticoid resistant asthmatics, clinical resistance to therapy could not be accounted for by differences in absorption and clearance of plasma prednisolone derived from orally administered prednisone. We have subsequently shown ([@b31]) that the inhibition of PHA-induced proliferation of peripheral blood T cells from asthmatics by glucocorticoids in vitro is reproducible both in the short term and when patients are re-tested after intervals of several months. This suggests that the degree of glucocorticoid sensitivity of peripheral blood T cells from asthmatics, and by inference their clinical sensitivity to glucocorticoid therapy, remains relatively constant, although there is evidence (see below) that sensitivity in individual patients may vary to some degree according to the ongoing severity of their disease.

Glucocorticoid resistant asthmatics are not Addisonian and do not have elevated plasma cortisol concentrations ([@b20]), suggesting that the impaired glucocorticoid responsiveness observed in their peripheral blood T cells is not a generalised, systemic phenomenon. One possibility is that impaired T cell glucocorticoid responsiveness in asthma may be induced by the action of pro-inflammatory cytokines within the local environment of the inflammatory process. In this regard, there exists evidence that the glucocorticoid receptor ligand binding affinity of peripheral blood T cells in asthmatics may be altered in the short term according to disease severity in vivo and by exposure to cytokines in vitro. The glucocorticoid receptor ligand binding affinities of peripheral blood T cells from a group of poorly controlled asthmatics were reduced as compared with normal controls (median K~d~ 29.0 vs 8.0 nM). Glucocorticoid therapy of these asthmatics, which was accompanied by clinical improvement, was associated with a significant increase in affinity of the T cell glucocorticoid receptors ([@b96]). In a detailed study of glucocorticoid receptor binding in peripheral blood mononuclear cells from glucocorticoid sensitive and resistant asthmatics, two distinct abnormalities were observed ([@b92]). The majority of the asthmatics (15 out of 17) demonstrated a significantly reduced receptor binding affinity (mean K~d~ 42.1 nM) as compared with sensitive patients (mean K~d~ 21.6 nM) and normal controls (mean K~d~ 7.9 nM). This abnormality was confined to T cells, reverted to normal after culture of the T cells in vitro for 48 hours, but could be sustained by culture in the simultaneous presence of high concentrations of IL-2 and IL-4. The remaining two glucocorticoid resistant asthmatics had abnormally low numbers of nuclear glucocorticoid receptors with normal binding affinity. This abnormality was not confined to T cells and was not influenced by the presence of exogenous cytokines. It was further shown ([@b49]) that this abnormality could be induced by culture of peripheral blood T cells from normal donors with IL-2 and IL-4 in vitro, and that this induction was associated with a reduced inhibitory effect of methylprednisolone on the proliferation of the T cells induced by phorbol ester and ionomycin. A similar effect of exogenous IL-13 alone was subsequently demonstrated in monocytes ([@b97]). The intrinsic physiological significance of these relatively small changes in ligand binding affinity of the glucocorticoid receptor is difficult to assess, but clearly they may contribute to glucocorticoid refractoriness. More likely, they may represent an epiphenomenon reflecting more fundamental changes in the properties of the glucocorticoid receptor in T cells following exposure to cytokines (see below).

There exists similar evidence for a differential effect of glucocorticoids on T cells from sensitive and resistant asthmatics in vivo ([@b67]). In this study, bronchoalveolar lavage was performed in glucocorticoid sensitive and resistant asthmatics before and after a course of oral prednisone, and expression by BAL cells of mRNA encoding cytokines was measured by in situ hybridization. Whereas prednisone therapy of the glucocorticoid sensitive asthmatics was associated with reductions in the percentages of BAL cells expressing mRNA encoding IL-4 and IL-5 and elevation of the percentages of cells expressing mRNA encoding IFN-γ, only a decrease in the percentages of cells expressing mRNA encoding γ was observed in association with prednisone therapy of the glucocorticoid resistant asthmatics. In addition, compared with the sensitive asthmatics, the resistant patients had elevated percentages of BAL cells expressing mRNA encoding both IL-2 and IL-4 at baseline. These data are compatible with the hypothesis that glucocorticoids exert differential effects on cytokine mRNA expression in T cells from glucocorticoid sensitive and resistant asthmatics in vivo. The authors also speculated that the local elevated expression of IL-2 and IL-4, at least at the level of mRNA, in these patients might have been responsible for some of the glucocorticoid refractoriness of the cells described in the in vitro experiments above.

Although glucocorticoids generally reduce inflammation by inhibiting the production of pro-inflammatory cytokines, one interesting facet of glucocorticoid action, which is receiving increasing attention, is their ability to increase the production of the anti-inflammatory cytokine interleukin-10 (IL-10). Studies in patients, initially in transplantation ([@b104]), and more recently in other conditions including asthma ([@b48]), have demonstrated that administration of glucocorticoids, intravenously or by inhalation, results in a significant increase in systemic or local IL-10 synthesis respectively. Parallel studies from our own laboratories have shown a concentration-dependent induction by glucocorticoids of T cell IL-10 expression *in vitro* ([@b87]). Interest in the possible therapeutic benefit of IL-10 in asthma already exists, based on its proposed role in regulating immune homeostasis in the lung ([@b3]). IL-10 inhibits pro-inflammatory cytokine production, antigen presentation, T cell activation and mast cell and eosinophil function (reviewed by [@b76]). Furthermore, synthesis of IL-10 is deficient in the airways of asthmatics as compared with controls ([@b9]), and polymorphisms of the IL-10 gene leading to impaired expression of IL-10 are associated with a more severe disease phenotype ([@b70]). We have recently described a marked deficiency in the capacity of CD4^+^ T cells from glucocorticoid resistant asthmatics to synthesize IL-10 following *in vitro* stimulation in the presence of dexamethasone, as compared with sensitive patients of equivalent disease severity ([@b38]). We have furthermore shown that vitamin D3 in combination with glucocorticoids can restore the ability of blood CD4 T cells from patients with glucocorticoid resistant asthma to manufacture IL-10 in quantities comparable with those of sensitive patients, and that oral administration of vitamin D3 to glucocorticoid resistant asthmatics for seven days enhanced ex vivo responses of their T cells to glucocorticoid ([@b111]).

Molecular basis of glucocorticoid action and resistance
-------------------------------------------------------

Observations made in the past few years have greatly increased our knowledge of how the GR regulates transcription, and how this process may be modified both in vitro and in vivo. The GR comprises three domains, the N-terminal or immunogenicity domain, the central DNA-binding domain and the C-terminal ligand-binding domain ([@b58]; [@b46]). The GR in its ligand-unbound state is located primarily in the cytoplasm as part of hetero-oligomeric complexes containing the heat shock proteins 90, 70 and 50. Upon binding to ligand, the GR undergoes conformational changes, dissociates from the heat shock proteins, homodimerizes and translocates to the nucleus. There, the ligand-activated GR may interact with DNA sequences (glucocorticoid response elements) or with other transcriptional regulators through protein/protein interactions, directly influencing the activity of the latter on their target genes ([Figure 1](#fig1){ref-type="fig"}).

![Mechanism of glucocorticoid action. After diffusion across the cytoplasmic membrane, glucocorticoid (GC) binds to the glucocorticoid receptor (GR) which dissociates from heat shock protein 90 (HSP90) then dimerises. In the cell cytoplasm it may interact with transcriptional regulatory proteins such as AP-1; such interactions are mutually inhibitory. Nuclear translocation of the ligand bound GR is regulated by chemical modifications, such as phosphorylation, and possibly other mechanisms. Once inside the nucleus, the ligand bound receptor may interact directly with binding regions (glucocorticoid regulatory elements, GRE) adjacent to genes, either increasing (A) or decreasing (B, negative GRE) transcription of these genes. More usually, however, the ligand-bound GR interacts with DNA as part of a highly dynamic complex of proteins including transcriptional regulatory proteins such as AP-1, NFκB and cyclic AMP response element binding protein (CREB) (see text). The complexity of these interactions in individual cells accounts for the remarkable variability of glucocorticoid actions on cells according to their function and phenotype.](tcrm0305-771-01){#fig1}

Proteins which may bind directly to the GR and modulate its activity in this way include AP-1, NFκB, signal transduction and activators of transcription (STATs) and certain of the CCAAT-enhancer binding proteins (C/EBP). These interactions appear to be particularly important in glucocorticoid-mediated suppression of inflammation, and may allow the activated GR to transrepress expression of cytokine genes without binding to DNA at all ([@b86]).

### Interaction of GR with AP-1

The pro-inflammatory transcriptional element activator protein-1 (AP-1) is an important contributor to the expression of the asthma-relevant Th2 cytokines IL-4, IL-5 and IL-13. AP-1 comprises of variable heterodimers of Jun (c-Jun, JunB and JunD) and Fos (c-Fos, FosB, Fra1 and Fra2) family members. AP-1 is inducible by a variety of cytokines and growth factors ([@b66]), and also by oxidative stress (see above). It is activated through the phosphorylation of c-Jun and the transcriptional regulation of c-Fos ([Figure 2](#fig2){ref-type="fig"}). Phosphorylation of c-Jun is the end result of the action of a trilayer of kinases ([@b24]). c-Jun itself is phosphorylated by Jun-N-terminal kinase (JNK), a member of the extracellular signal-related kinases/mitogen-activated protein kinases (ERK/MAPK) family of serine/threonine kinases. JNK is in turn activated by phosphorylation by JNK kinase, a member of the MAPK/ERK kinase (MEK) family of kinases that phosphorylate on both a tyrosine and a threonine or serine residue. Of the seven members of the MEK family, MEK4 or Jun-N-terminal kinase kinase is principally responsible for the phosphorylation of JNK. At the top end of the trilayer, the most upstream kinases in the cascade, are the MEK kinases (MEKK), serine/threonine kinases that are diverse in sequence and structure ([Figure 3](#fig3){ref-type="fig"}).

![Regulation of activation of c-fos and c-jun, the components of AP-1. Transcription of c-fos is induced by serum response factor (SRF) which binds to the serum response element (SRE) adjacent to the c-fos gene. SRF is activated by phosphorylation by ELK-1, which is in turn activated by phosphorylation by a range of MAP kinases including ERK-1/2 and JNK (see text). Phosphorylated JNK also phosphorylates and activates c-jun, which together with c-fos forms the heterodimer complex AP-1. AP-1 increases the transcription of a number of asthma-relevant cytokine genes such as interleukin (IL)-4 and IL-5. This activity is inhibited by interaction with the ligand bound glucocorticoid receptor (GR) (see text and [Figure 1](#fig1){ref-type="fig"} above). IL-4 and IL-5 may in turn further stimulate MAP kinase activity, forming a positive, feed-forward loop. Many other stimuli, including oxidative stress may also activate MAP kinases.](tcrm0305-771-02){#fig2}

![The tri-layer of kinases which activate c-jun. Environmental cytokines, ultraviolet light, serum factors, oxidative stress and many other stimuli phosphorylate and activate MEKK-1/4 through the Ras/Rho family of small GTP-binding proteins as shown. MEKK1 in turn phosphorylates JNKK1, which phosphorylates JNK, which binds to and phosphorylates c-jun, the active component of AP-1 (see text and [Figure 2](#fig2){ref-type="fig"} above), and the regulatory protein activating transcription factor-2 (ATF-2). Phosphorylation may occur on threonine or tyrosine residues.\
**Abbreviations:** GT(D)P, guanosine tri(di)phosphate; JNK, c-jun N-terminal kinase; JNKK1, c-jun N-terminal kinase kinase-1; MEKK-1/4, MAPK/ERK kinase kinase-1/4; SAPK, serum activated protein kinase; Ser, serine; SOS, son of sevenless; Thr, threonine; Tyr, tyrosine.](tcrm0305-771-03){#fig3}

In collaboration with Professor Ian Adcock at Imperial College, London, we have implicated abnormal regulation of AP-1 in the mechanism of glucocorticoid resistance. We showed that glucocorticoid-exposed peripheral blood mononuclear cells from glucocorticoid-resistant, as compared with glucocorticoid-sensitive asthmatics have fewer activated GR available for DNA binding (Adcock et al 1995a), but elevated DNA binding of AP-1 following phorbol ester stimulation (Adcock et al 1995b). These cells also demonstrated significantly elevated basal, as well as phorbol ester-stimulated, transcription and translation of c-Fos. Furthermore, phorbol ester stimulation of cells from glucocorticoid-sensitive patients induced a glucocorticoid-resistant phenotype, which was associated with direct interaction between the activated GR and c-Fos, detected by co-immunoprecipitation ([@b63]). Binding of GR to other pro-inflammatory transcriptional activators (such as CREB and NFκB) was unaffected. We interpret these data to suggest that mononuclear cells from glucocorticoid-resistant asthmatics inappropriately over-express AP-1, which sequesters and neutralises activated GR, thus causing refractoriness to glucocorticoid-induced inhibitory responses. More recently we have shown that ([@b72]) that systemic glucocorticoid therapy of glucocorticoid sensitive, but not resistant, asthmatics is associated with down-regulation of phosphorylation of both c-Jun and JNK within inflammatory cells within the bronchial mucosa, further underlining a critical role for AP-1 components in regulating glucocorticoid response in asthma. The reason for this failure of glucocorticoid to down-regulate the c-Jun/JNK/MEK cascade in clinically resistant patients is presently unclear, but may reflect influences of the local cytokine milieu in these patients (such as elevated IL-2/IL-4 expression, as described above, which may enhance AP-1 production ([@b105])) and/or the influences of environmental stimuli such as oxidative stress or microbial superantigens as described above.

### The role of p38 MAP kinase

p38 MAP kinase is another member of the family of MAPK/ERK molecules. Its activity is regulated by phosphorylation, principally by the p38 MAP kinases MEK3 and MEK6. A recent study ([@b43]) has raised the intriguing possibility that changes in the binding affinity of nuclear GR induced by exposure to IL-2/IL-4 may be caused by direct phosphorylation of the GR at serine 226 secondary to the resulting activation of p38 MAP kinase. Although this study did not directly demonstrate that p38 MAP kinase phosphorylation of the GR is responsible for its reduced binding affinity for glucocorticoids or its defective induction of an inhibitory signal, the hypothesis is certainly plausible. Similarly TNF-α has been shown to induce glucocorticoid resistance in normal human monocytes, possibly through activation of p38 MAP kinase in addition to NF-κB ([@b30]). Several other protein kinases, such as JNK, may also modify activity of the GR in this way, either directly or through phosphorylation of co-factor molecules ([@b60]; [@b90]).

The findings with p38 MAP kinase raise the possibility that the small alteration in ligand binding affinity of the nuclear GR induced by IL-2/IL-4 exposure is an epiphenomenon reflecting more fundamental alterations in the function of the GR brought about by phosphorylation. This is in line with the fact that the observed changes in ligand-binding affinity of the GR are relatively small and of doubtful physiological significance per se. Such a fundamental alteration in GR function is also suggested by the fact that serine 226 is located in the N-terminal domain of the GR, remote from the ligand-binding pocket which resides in the C-terminal portion of the molecule. There is some precedent for the possibility that remote regions of the GR may mutually interact. For example, there are two trans-activation domains, activation functions (AF) 1 and 2, situated respectively in the immunogenic and DNA-binding domains of the GR, which co-contribute to the full activity of the GR molecule on its responsive promoters. Conceivably, phosphorylation at a remote site might effect such interactions. Furthermore, both AF1 and AF2 interact with several other nuclear proteins and protein complexes, such as members of the p160 family and the co-activators p300/cyclic AMP-responsive element-binding protein (CREB)-binding protein (CRP) ([@b40]) which can affect the glucocorticoid-titration response of GR transactivation of its responsive promoters ([@b101]).

### The role of mitogen-activated extracellular signal-related kinases (MEK)

In one further recent study ([@b69]), stimulation of T cells with enterotoxin superantigen produced by *Staphylococcus aureus* rendered them resistant to GC inhibition in vitro, and this was accompanied by phosphorylation of both the mitogen-activated extracellular signal-related kinase (MEK/ERK) signaling protein and the GC receptor itself, as well as its impaired nuclear translocation. Treatment of cells with MEK/ERK inhibitors abrogated all of these effects. The authors inferred that activation of the MEK/ERK signaling pathway renders T cells resistant to GC inhibition by direct, ERK-mediated phosphorylation of the GC receptor which impairs its nuclear translocation. The effects of external environmental factors such as staphylococcal colonization on GC responsiveness emphasize the possibility that environmental factors may influence this responsiveness in individual patients.

### The role of the GRβ-isoform

The β-isoform of the GR is a splice variant of the "normal" GR, or GRα. The splicing varies in the choice of a splice acceptor site in exon 9. The cDNA sequence up until this point encodes a common region of 727 amino acids. Thereafter, the GRα splice adds 50 amino acids whereas the β isoform has only a further 15 residues. The consequence of this alternative splice was shown to be an inability of the β isoform to bind ligand ([@b81]). The reason for this has been clarified by the recent crystallization of the GR ligand-binding domain complexed with dexamethasone and a peptide that was homologous to the GR interaction domain of the co-activator TIF2 ([@b8]). This study demonstrated that the amino acids of the receptor bind to ligand through either hydrogen bonds or hydrophobic interactions. One residue forming a hydrogen bond (T739) and seven residues forming hydrophobic interactions (L732, Y735, C736, T739, I747, F749 and L753) are present within the a, but are absent from the β isoform.

Artificial transfection of cells with GRβ can inhibit GRα-mediated stimulation of gene expression, \[[@b81]; [@b107]). The popular theory to explain this is that it acts as a dominant negative inhibitor of GRα activity (but see reservations below). Physiological expression of GRβ in neutrophils has been suggested as a possible cause of their relative refractoriness to glucocorticoid inhibition ([@b100]). Several studies suggest that GRβ may be induced in cell lines to an extent sufficient to induce glucocorticoid resistance by pro-inflammatory cytokines such as TNF-α ([@b107]), possibly reflecting the location of a consensus NF-κB binding sequence in the 5-flanking sequences of the GR gene. Furthermore, increased GRβ immunoreactivity has been reported in peripheral blood mononuclear cells and bronchoalveolar lavage cells from patients with glucocorticoid-resistant asthma ([@b35]), although possible modulation of expression in association with glucocorticoid therapy was not explored. In studies from our own laboratory using a model of tuberculin-induced cutaneous inflammation, we reported elevated expression of GRβ immunoreactivity in inflammatory cells infiltrating the skin lesions in glucocorticoid resistant, as compared with sensitive asthmatics ([@b95]). Treatment of the patients with systemic glucocorticoids was associated with down regulation of GRα expression in the glucocorticoid sensitive, but not the resistant patients.

Notwithstanding these observations, it seems likely that there is much yet to be learned about the possible functional role of GRβ. In this context it is possible to speculate on how GRβ may influence transcriptional activation mediated by GRα and its binding to the glucocorticoid response element (GRE), transcriptional repression mediated by GRα binding to negative GREs and inhibition of transcriptional activation mediated by sequestration of transcription factors:

### Effects of GRβ on transcriptional activation

In terms of transcriptional activation, the classical role of GRα is to bind ligand, to dimerize and then to bind to GRE. This binding permits the recruitment of co-activator complexes, because one of the consequences of ligand binding for nuclear hormone receptors is a reduction in their affinity for co-repressor complexes, and replacement of these complexes with co-activators. The crystallization data referred to above ([@b8]) indicate that GRβ lacks residues forming the charge clamp required for docking of the amino terminus TIF2 LXXLL motif, suggesting that GRβ may be unable to recruit co-factors required for transcriptional activation. Thus GRβ, by displacing GRα, could conceivably act as a dominant negative inhibitor of transcriptional activation. There are, however, uncertainties regarding this conclusion. In the first place, GRβ seems to be expressed in much lower quantities (typically 10- to 100-fold less, at least at the level of mRNA expression) than GRα. In the second place, whereas in the case of GRα ligand binding appears to be a prerequisite for nuclear translocation, it is not known what governs the cytoplasmic/nuclear partitioning of GRβ or if it is present in sufficient quantities in the cellular nucleus. Finally, it is unlikely that GRβ could dimerise efficiently, so that its ability to compete for binding with high affinity to GREs is questionable.

### Effects of GRβ on transcriptional repression

Repression mediated by ligand-bound GR is thought to occur through binding to atypical sites on DNA, for example non-consensus NFAT/AP-1 sites, rather than binding to GREs. At these sites, it is thought that the conformation of the DNA binding site, and the influence of locally bound factors might cause the GR to adopt a structure that is not permissive for recruitment of co-activators, but rather permissive for recruitment of co-repressors. There is at present no information as to whether or not GRβ can bind to such sites and, more importantly, recruit co-repressor complexes.

### Inhibition of transcriptional activation mediated by sequestration of transcription factors

So far, there has been no clear demonstration for a role for the extreme carboxy-terminus of the GR in the sequestration (and inactivation) of transcriptional activating proteins such as AP-1. It is conceivable, therefore, that both GRα and GRβ could exert repressive effects on gene expression by sequestration of such transcriptional activators.

### The possible role of histone proteins

DNA is packaged into chromatin, a highly organized and dynamic protein-DNA complex. The N-terminal tails of the core histone proteins contain highly conserved lysine residues that are sites for post-translational acetylation. Acetylation of histone residues results in unwinding of the DNA coiled around the histone core. This process opens up the chromatin structure, allowing transcriptional factors and RNA polymerase II to bind more readily to DNA, thereby increasing gene transcription ([@b42]). The large co-activator molecule CREB binding protein (CBP) that binds to the basal transcriptional apparatus has intrinsic histone acetyl transferase (HAT) activity. Additionally, associated co-activator proteins, including steroid receptor co-activator-1 (SRC-1), transcription factor intermediary factor--2 (TIF2), p300/CBP co-integrator-associated protein (p/CIP) and glucocorticosteroid receptor enhancing protein-1 (GRIP-1) may enhance local HAT activity. In genes which are induced by glucocorticoids, high concentrations of glucocorticoids cause binding of the activated GR to CBP and/or associated co-activators, resulting in histone acetylation on lysines 5 and 16 of histone H4 and increased gene transcription. HAT activity may be further enhanced by binding of transcriptional regulatory proteins such as AP-1 and NF-κB ([@b47]; [@b42]). Repression of genes is conversely associated with a reversal of this process by histone deacetylation, mediated by histone deacetylases (HDACs) ([@b83]). HDACs comprise of a growing family of enzymes of which at least 10 mammalian members have been described ([@b7]). Some, such as HDAC4 and HDAC8 are able to shuttle between the cellular nucleus and cytoplasm.

Histone acetylation is a dynamic process in which small changes in acetylase and deacetylase activity can considerably alter the net HAT activity at any particular gene promoter site. Suppression of HAT activity, as well as recruitment of HDAC activity to active transcriptional complexes may play a role in glucocorticoid regulation of gene transcription ([@b44]). This may occur in a variety of ways. Glucocorticoid repression may reflect competition between the activated GR and the binding sites on CBP for other transcriptional activating proteins, such as AP-1 ([@b52]), NF-κB, Sp1, Ets, NF-AT and STATs, which may alter local HAT activity. Alternatively, and not exclusively, the GR may bind to one of several co-repressor molecules such as RIP140, NCoR1 and GRIP1which in turn associate with proteins having differing HAT activity ([@b26]). These complex interactions probably play a major role in the genesis of the infinitely variable and subtle effects of glucocorticoids on individual target cells.

Clearly, then, intrinsic abnormalities of, or external influences on the regulation of HAT activity in individual cells may influence their glucocorticoid responsiveness. Already there are suggestions that external influences such as exposure to cigarette smoke, an oxidative stress, may inhibit the anti-inflammatory actions of glucocorticoids on cells in the lungs of smokers by reducing HDAC expression and activity ([@b45]). Similar phenomena may contribute to glucocorticoid resistance in asthma.

Genetic basis of glucocorticoid resistance
------------------------------------------

The glucocorticoid receptor gene itself is a plausible candidate for a genetic basis to glucocorticoid resistance. A missense mutation in this gene had previously been found to be responsible for the phenomenon of familial glucocorticoid resistance ([@b41]). These patients have a markedly reduced affinity of the glucocorticoid receptor for ligand and clinically have features of Addison's disease, which is not the case with glucocorticoid resistant asthmatics. Analysis of the sequence of the glucocorticoid receptor protein in six resistant and sensitive patients showed no mutations in any of the subjects ([@b62]). Although this work is ongoing, there is no obvious mutation that might account for glucocorticoid resistance. Obviously, relevant mutations do not necessarily have to be within the coding region of the receptor gene itself, but could be in genes encoding products in downstream signaling pathways.

In addition to this, glucocorticoid responsiveness may be governed at least partly by genetic factors. For example, one study suggested that inherited anomalies might render approximately 7% of the normal population relatively hypersensitive to glucocorticoids ([@b61]). Indeed, there is marked variability in the sensitivity of T cells even from normal individuals to glucocorticoid inhibition in vitro, suggesting that the phenomenon may not be induced entirely by inflammation but may be partly heritable.

The technique of positional cloning provides a way to identify genes or gene complexes which predispose to disease in an unbiased fashion. Using this technique, five genes or gene complexes (ADAM33, PHF11, DPP10, GPRA and SPINK5) have been linked with predisposition to asthma (reviewed by [@b18]), and studies are ongoing to investigate the functions of these genes, some of which, along with others to be discovered, may play a role in therapy resistant asthma. These studies involve large numbers of patients, but larger studies still will be needed to discern the relative contribution of genetics and environment in regulating asthma severity and responsiveness to therapy in individual patients. A further complication is that different genes may contribute variably to asthma in different racial groups.

The alternative approach to genetic analysis is to look for variability in the expression of "candidate genes" (that is, those hypothesized to be an important part of the disease process or in governing responsiveness to therapy), for example between asthmatics and controls or between glucocorticoid sensitive and resistant asthmatics. The list of such "candidate genes" is potentially very large, and the problem with this approach is that it is impossible to know the relative importance, and possible physiological significance of any differences uncovered. This process is being facilitated by microarray gene fingerprinting, which allows analysis of the differential expression of potentially many thousands of genes on a single chip. Using this technique in an Icelandic population it was possible to define a gene expression fingerprint which predicted glucocorticoid resistant, as compared with sensitive asthma not only in the population of origin but also in an independent cohort ([@b33]). Again such analysis might be confounded by ethnicity. Genes may also regulate drug metabolism variably in different individuals ([@b34]).

Management of glucocorticoid resistant asthma
---------------------------------------------

In view of the above, a proposed list of techniques for the investigation of "difficult" asthma, including glucocorticoid resistant asthma, is proposed in [Table 3](#tbl3){ref-type="table"}. Such investigation would also include a formal trial of glucocorticoid therapy to investigate possible glucocorticoid resistance defined by the criteria discussed above. Key features of the management of severe asthma have much in common with the management of any patient with asthma. It is critical to make an accurate diagnosis, minimize factors which may induce loss of asthma control and ensure good compliance with therapy.

###### 

Investigation of difficult/therapy resistant asthma

  -------------------------------------------------------------------------------------------------------
  **Assessment of severity**
  Symptom score chart and use of β2-agonist reliever therapy
  Spirometric measurement of lung volumes and gas transfer
  Bronchial responsiveness to methacholine/histamine
  Diurnal variation in peak expiratory flow
  Quality of life assessment
  **Determination of pharmacological responsiveness**
  Assessment of compliance to therapy and inhaler technique
  Bronchodilator response to β2-adrenergic agonists
  Response to prednisolone (corticosteroid-responsiveness)
  **Radiology**
  Chest radiograph
  Barium swallow
  Computed tomography of sinuses
  High-resolution computed tomography of sinuses
  **Blood tests**
  Full blood count, including eosinophil count
  Serum IgG, IgA, IgM and IgG subclasses[\*](#tf3-1){ref-type="table-fn"}
  Serum total IgE
  Specific IgE to selected allergens
  Thyroid function tests
  **Other tests**
  Biomarkers of inflammation (exhaled nitric oxide, eosinophils in induced sputum)
  Sweat test and genetic assessment of CFTR[\*\*](#tf3-2){ref-type="table-fn"} mutations (if indicated)
  24-h oesophageal pH monitoring
  Examination of nasopharyngeal airways
  Tests of ciliary function
  Skin prick test to common aeroallergens
  Fibreoptic bronchoscopy with bronchial biopsy and bronchoalveolar lavage
  Psychological assessment
  -------------------------------------------------------------------------------------------------------

**Notes:** Ig -- immunoglobulin

CFTR -- cystic fibrosis transmembrane conductance regulator

By definition, the "difficult" asthmatic will be receiving high dosages of inhaled glucocorticoid therapy, often together with oral glucocorticoids. Generally all patients with severe asthma, particularly those admitted as an emergency will be treated with systemic glucocorticoids at high dosage for at least two weeks. It is only in the fullness of time that a pattern of glucocorticoid responsiveness is established. In patients thought to be truly glucocorticoid resistant (that is, patients showing the proscribed failure in FEV~1~ response when the diagnosis is confirmed and aggravating conditions excluded), further long-term therapy with systemic glucocorticoids is probably inadvisable since there is little evidence that these drugs will influence asthmatic symptoms and disease activity, but may on the other hand cause considerable unwanted effects. In such cases it may be sensible to reduce or withdraw glucocorticoids and treat instead with adequate dosages of alternative anti-asthma drugs such as bronchodilators, leukotriene receptor antagonists and immunosuppressive drugs (see below). In clinical practice, however, because there is little hard evidence to justify withdrawal of systemic glucocorticoids from any severe asthmatic patient, this process is often ignored or delayed. Furthermore, it is not clear on clinical grounds whether glucocorticoid responsiveness is induced or enhanced by the use of glucocorticoids themselves (although reduction of asthmatic inflammation would appear to be associated with an increased affinity of the glucocorticoid receptor for binding to its ligand, as discussed above). In view of the possibility that glucocorticoid sensitivity may change with time, it would seem prudent to re-assess glucocorticoid sensitivity periodically ([@b25]) although, as discussed above, within individuals T cell glucocorticoid sensitivity appears to be relatively stable at least over a period of months.

The observation that glucocorticoid responsiveness of asthmatics correlates with glucocorticoid inhibition of their T cells suggests that other drugs that inhibit T cells might be useful for asthma therapy, in particular drugs that inhibit T cells by mechanisms distinct from those of glucocorticoids. We have shown (Corrigan et al 1991; [@b31]) that the immunosuppressive drugs cyclosporin A, rapamycin and mycophenolate mofetil inhibit proliferation of T cells from glucocorticoid sensitive and resistant asthmatics to an equivalent extent. It has been shown ([@b4]; [@b71]) that cyclosporin A, when administered to patients with poorly controlled asthma despite continuous systemic glucocorticoid therapy, improved lung function while allowing reduction of oral glucocorticoid dosages in a proportion of the patients. Similarly concomitant therapy of glucocorticoid dependent asthmatics with methotrexate ([@b93]) or gold salts ([@b59]) has been shown in some trials to spare glucocorticoid therapy, although no trials have suggested that these agents improve lung function. In general, none of these agents is particularly satisfactory in the sense that many patients fail to respond and it is impossible to predict responsiveness a priori. Furthermore, chronic immunosuppression raises the risk of development of serious infection or malignancy, and there is in addition a list of not insignificant unwanted effects associated, in some patients, with the use of each particular drug. An urgent appraisal of other immunosuppressive drugs or cytokine inhibitory strategies is needed in glucocorticoid dependent and glucocorticoid resistant asthma. It is a priority to produce a global definition of which patients are suitable for treatment, and what constitutes an adequate trial of therapy. It will also be essential to develop cheap and reliable biomarkers of airways inflammation and remodeling so that glucocorticoid responsiveness can be assessed accurately and objectively in the short and long term.
